

Health economics for stratified medicine

5 October 2016, 09.30 – 19.00

Academy of Medical Sciences, 41 Portland Place, London W1B 1QH

09.15-09.45	Registration
09.45-09.50	Welcome Professor Sir Munir Pirmohamed FMedSci (Chair), David Weatherall Chair of Medicine, University of Liverpool
09.50-10.10	Key issues in the health economics of stratified medicine Professor Adrian Towse, Director, Office of Health Economics
10.10-10.30	Modelling efficacy of stratified medicines Professor Katherine Payne, Professor of Health Economics, University of Manchester
10.30-10.50	Health economics and drug safety Professor Dyfrig Hughes, Co-Director of the Centre for Health Economics & Medicines Evaluation, Bangor University
10.50-11.10	NICE evaluation of stratified medicines Dr Sarah Byron, Senior Technical Adviser, Observational Data Unit, National Institute for Health and Care Excellence
11.10-11.40	Tea and coffee
11.40-12.00	Health economics for stratified medicine - industry perspective Gavin Lewis, Global Head Oncology Market Access, AstraZeneca
12.00-12.20	Health economics for stratified medicine - patient perspective Alastair Kent OBE, Director, Genetic Alliance UK
12.20-12.50	Panel discussion
12.50-13.50	Lunch
Building an evidence base for the evaluation of stratified medicines	
13.50-14.00	Introduction to the workshop sessions Professor Sir Munir Pirmohamed FMedSci (Chair), David Weatherall Chair of Medicine, University of Liverpool
14.00-15.30	Break-out sessions 1. Health economics in stratified medicine – the evidence gaps and research priorities <i>Chair: Professor Katherine Payne, University of Manchester</i> 2. Assessing the health economics of stratified medicine from the healthcare perspective to facilitate uptake of innovation <i>Chair: Professor Dyfrig Hughes, Bangor University</i> 3. Stratified medicine health economics: the perspective of the patient and public <i>Chair: Professor Sarah Garner, National Institute for Health and Care Excellence</i>
15.30-15.50	Tea and coffee
15.50-16.30	Feedback and conclusions Open discussion with audience.
16.30	Close